[Newly diagnosed multiple myeloma: Do we need to propose thromboprophylaxis?].
The incidence of venous thromboembolism in multiple myeloma depends on the disease characteristics that include recent diagnosis, persistent or recurrent multiple myeloma, patient characteristics, and the type of treatment received such as thalidomide or lenalidomide especially in combination with high-dose dexamethasone, or combined chemotherapy. Currently, recommendations could be challenged by the results of the first randomized study evaluating aspirin, low molecular weight heparins and vitamin K antagonists in the antithrombotic prophylaxis. The recent data from the literature show that it is not possible to propose a therapeutic management for venous thromboembolism prophylaxis in multiple myeloma and that the use of antithrombotic prophylaxis may not be mandatory.
Service de médecine interne, hôpital Nord, CHU de Saint-Étienne, 42055 Saint-Étienne, France. sdb.e@hotmail.fr
E
E
Chalayer
K
K
Augeul-Meunier
B
B
Tardy-Poncet
P
P
Cathebras
D
D
Guyotat
B
B
Tardy
D018890:Chemoprevention / Q000706:statistics & numerical data*; D042241:Early Diagnosis; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006301:Health Services Needs and Demand; D006801:Humans; D015994:Incidence; D009101:Multiple Myeloma / Q000150:complications / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy*; D012307:Risk Factors; D013997:Time Factors; D054556:Venous Thromboembolism / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*
D005343:Fibrinolytic Agents